The KQ Labs accelerator has opened applications for its ninth cohort, giving early-stage health tech start-ups a new opportunity to access mentoring, investor networks and specialist support in data-driven healthcare innovation.
The five-month programme is delivered by the Francis Crick Institute, with support from Medicines Discovery Catapult and Cancer Research Horizons. It is designed for companies working in areas such as drug discovery, digital health, artificial intelligence and precision medicine.
Up to ten start-ups will be selected for the 2026 cohort. Successful applicants will receive tailored guidance to help refine their technologies, strengthen their business models and prepare for future investment.
Applications are open until midnight on Wednesday, 12 August.
KQ Labs accelerator targets data-driven health innovation
The KQ Labs accelerator focuses on start-ups using data and advanced technology to solve major healthcare challenges.
This includes companies developing tools for AI-powered drug discovery, digital health platforms, precision medicine solutions and other technologies that could improve how diseases are diagnosed, treated or managed.
The programme is aimed at early-stage businesses that have strong scientific ideas but need support turning those ideas into commercially viable companies.
For founders in health tech, that support can be critical. Scientific innovation alone is rarely enough to build a successful company. Start-ups also need clear market strategies, investor readiness, regulatory awareness and access to industry networks.
That is where the KQ Labs accelerator aims to make a difference.
What the 2026 KQ Labs accelerator cohort will receive
Start-ups selected for the 2026 KQ Labs accelerator will take part in a five-month programme built around practical company development.
The support includes mentoring, expert-led workshops, investor engagement and access to pharmaceutical and funding networks. These resources are designed to help founders sharpen their business plans and move closer to commercial growth.
Participants will also receive guidance on how to position their technology, communicate with investors and prepare for partnerships in the healthcare and life sciences sectors.
For early-stage companies, this kind of structured support can help reduce common risks. Many promising health tech businesses struggle not because their science is weak, but because they lack access to the right commercial advice, funding routes and industry contacts.
The programme gives founders a chance to close that gap.
Why the KQ Labs accelerator matters to UK health tech
The KQ Labs accelerator has become an important launchpad for data-driven health companies in the UK.
Since it launched in 2018, the programme has supported 70 start-ups. Together, those companies have raised more than £230 million in funding.
That track record shows the growing importance of data-led innovation in healthcare. As artificial intelligence, computational biology and digital health tools become more advanced, start-ups are playing a bigger role in shaping the future of medicine.
The UK already has a strong life sciences ecosystem, with world-class research institutions, hospitals, universities and investors. Programmes such as KQ Labs help connect scientific talent with the commercial support needed to bring new technologies to market.
This is especially important in fields such as precision medicine and AI-driven drug discovery, where innovation requires both deep scientific expertise and strong business execution.
Start-ups will gain investor and industry access
One of the biggest benefits of the KQ Labs accelerator is access to investors and industry leaders.
Health tech start-ups often face a difficult path to funding. Investors want to see strong science, but they also need evidence of commercial potential, market demand and a realistic route to adoption.
The accelerator helps companies prepare for those conversations.
Through mentoring and investor engagement, founders can improve their pitches, strengthen their strategies and better explain the value of their technology.
The programme also connects participants with pharmaceutical and funding networks. These connections can help start-ups find potential partners, customers and investors as they move beyond the early development stage.
Support from leading health and research organisations
The KQ Labs accelerator is backed by major organisations in the UK health innovation ecosystem.
The Francis Crick Institute leads the programme, bringing its research expertise and entrepreneurship support to participating start-ups.
Medicines Discovery Catapult provides additional support for companies working to turn advanced science into practical healthcare solutions. Its involvement is particularly valuable for start-ups focused on drug discovery, computational science and translational medicine.
Cancer Research Horizons also supports the programme, helping connect innovators with expertise and networks in oncology and cancer-related technologies.
Together, these organisations give the accelerator a strong foundation in science, healthcare, business development and investment readiness.
KQ Labs accelerator supports AI and precision medicine
The KQ Labs accelerator is especially relevant as healthcare becomes more data-driven.
Artificial intelligence is already changing how researchers search for drug targets, analyse biological data and design new treatments. Precision medicine is also growing as healthcare moves toward therapies and diagnostics tailored to individual patients.
Start-ups are often at the centre of this shift. They can move quickly, test new ideas and develop specialist tools for complex healthcare problems.
However, health tech innovation can be expensive and highly regulated. Founders need more than technical skill. They need commercial knowledge, clinical insight and access to partners who understand the healthcare market.
The KQ Labs accelerator helps provide that support.
Demo Day highlights start-up progress
The latest KQ Labs Demo Day gave companies a platform to present their technologies to investors and industry figures.
Demo Day is a key part of many accelerator programmes because it allows start-ups to show progress, build relationships and attract potential funding.
For health tech companies, this exposure can be especially valuable. Investors and industry partners often want to see how a technology fits into the wider healthcare system before offering support.
Several companies from the latest cohort secured funding support and follow-on investment during the programme, showing how accelerator participation can create real commercial opportunities.
Founder support goes beyond funding
While investment is important, the KQ Labs accelerator also supports founders in other essential areas.
Mentoring from experienced biotech entrepreneurs can help start-ups improve governance, business structure and leadership decisions. These areas are often overlooked in the early stages but become increasingly important as companies grow.
Good governance helps start-ups build investor confidence. It also prepares them for partnerships, hiring, regulatory conversations and future fundraising.
By giving founders access to experienced advisers, the programme helps companies become more resilient and better prepared for long-term development.
Application deadline for the 2026 cohort
Applications for the ninth KQ Labs accelerator cohort close at midnight on Wednesday, 12 August.
The programme is expected to select up to ten start-ups for the 2026 cohort.
Companies working in data-driven health, digital health, drug discovery, precision medicine and related fields are likely to be among the strongest candidates.
For founders building healthcare technologies, the programme offers a chance to gain expert mentoring, industry exposure and access to networks that can support future growth.
Final thoughts
The KQ Labs accelerator continues to play a growing role in supporting early-stage health tech companies.
With applications now open for its ninth cohort, the programme is offering another group of start-ups the chance to strengthen their science, sharpen their commercial strategy and connect with investors.
As healthcare becomes more dependent on data, artificial intelligence and precision medicine, programmes like KQ Labs can help turn promising ideas into real-world solutions.
For start-ups looking to scale in the health innovation sector, the 2026 cohort could provide a valuable route into the UK’s life sciences ecosystem.
